Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Spero Therapeutics (SPRO) Tax Provisions (2023 - 2024)

Historic Tax Provisions for Spero Therapeutics (SPRO) over the last 2 years, with Q4 2024 value amounting to -$290000.0.

  • Spero Therapeutics' Tax Provisions fell 17493.54% to -$290000.0 in Q4 2024 from the same period last year, while for Sep 2025 it was $387000.0, marking a year-over-year decrease of 8659.97%. This contributed to the annual value of $2.6 million for FY2023, which is N/A changed from last year.
  • Latest data reveals that Spero Therapeutics reported Tax Provisions of -$290000.0 as of Q4 2024, which was down 17493.54% from $290000.0 recorded in Q3 2024.
  • In the past 5 years, Spero Therapeutics' Tax Provisions ranged from a high of $2.2 million in Q3 2023 and a low of -$290000.0 during Q4 2024